Bristol-Myers Squibb vs Kia: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Kia was founded in 1944 by Kim Chul-ho and is led by Ho Sung Song.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Kia
- Founded
- 1944
- Headquarters
- Seoul, South Korea
- Current CEO
- Ho Sung Song
- Employees
- 53,200
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Kia
Kim Chul-ho
Kia possesses a gritty, foundational founding story, rooted in the desperate industrial infancy of Korea, long before it became an automotive leader, starting entirely with the pragmatic, meticulous manufacturing of bicycle parts.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Kia
- Euisun Chung2005–present
Executive Chair, Hyundai Motor Group; Kia Board Member
Credited with starting the design-led turnaround that changed how buyers saw Kia.
Source - Han-woo Park2014–2020
Former President and CEO
Serving as CEO from 2014 to 2020, he successfully navigated severe geopolitical tensions (like the THAAD missile crisis in China that crushed sales) while heavily upgrading Kia's global brand perception.
Source - Ho Sung Song2020–present
President and Chief Executive Officer
Revenue grew from about $41.9 billion (KRW 59 trillion) in 2020 to ~$81 billion (KRW 114.1 trillion) in 2025, and the operating margin peaked at 11.8% in 2024 before tariffs cut it to 8.0% in 2025.
Source
Timeline: Bristol-Myers Squibb and Kia side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1944Kia
Founding of Kyungsung Precision Industry
Kim Chul-ho establishes a modest workshop in Seoul dedicated to the manufacturing of steel tubes and bicycle parts, laying the humble groundwork for what would eventually become a global automotive leader and a vital contributor to South Korea's post-war indus…
1974Kia
Launch of the Brisa, Kia's First Passenger Car
Kia launched the Brisa, its first passenger car, built at the Sohari plant that opened in 1973. Kia had built motorcycles and light trucks before this, and the Brisa made it a carmaker.
1986Kia
Launch of the Pride and Global Export Expansion
Through a partnership with Ford and Mazda, Kia returned to passenger cars with the Pride. Abroad it was sold as the Ford Festiva, and it gave Kia its first large export volumes.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
1998Kia
Hyundai Motor Acquires Kia
After Kia collapsed in the 1997 Asian financial crisis and went into court receivership, Hyundai Motor won the 1998 auction for it, beating Ford among other bidders. Kia stayed a separate brand within the new Hyundai Motor Group.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2006Kia
Recruitment of Peter Schreyer
The enterprise makes the radical decision to hire former Audi design chief Peter Schreyer as its head of design, initiating a profound aesthetic revolution that introduces the well-known tiger-nose grille and elevates the brand from a budget alternative to a p…
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2011Kia
Launch of the Optima and the Design Renaissance
The Schreyer-designed Optima (K5) sedan brought Kia's new design language to a wide audience and helped it charge more and reach new buyers.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2020Kia
Announcement of the 'Plan S' Strategy
Kia announced Plan S, its mid- to long-term strategy to move from a combustion-focused carmaker toward EVs, purpose-built vehicles and mobility services. In January 2021 it renamed itself Kia Corporation.
2021Kia
Launch of the EV6 and the E-GMP Platform
The company introduces the award-winning EV6, the first dedicated electric vehicle built on the modular E-GMP platform, showcasing ultra-fast 800-volt charging capabilities and groundbreaking design, instantly establishing the enterprise as a serious technolog…
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2023Kia
EV9 Launch
Kia launched the EV9, a three-row electric SUV on the E-GMP platform, which went on to win the 2024 World Car of the Year award.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Kia
FY2025 Revenue Reaches KRW 114.141 Trillion
Kia sold a record 3,135,873 vehicles and reported FY2025 revenue of ~$81 billion (KRW 114.1 trillion) (+6.2%). Operating profit fell 28.3% to ~$6.45 billion (KRW 9.08 trillion) as US tariffs cost more than $2.13 billion (KRW 3 trillion).
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Kia
2030 Targets Set at CEO Investor Day
At its April 2026 CEO Investor Day, Kia set 2030 targets of ~$121 billion (KRW 170 trillion) in revenue, a 10% operating margin and 4.13 million sales. Q2 2026 revenue was a record ~$23.5 billion (KRW 33.04 trillion).
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Kia
- Takeover by Hyundai Motor (Kia acquired)1998Undisclosed
- Asia Motors1976Undisclosed
Questions about Bristol-Myers Squibb vs Kia
Who is the CEO of Bristol-Myers Squibb Company and Kia Corporation?
Bristol-Myers Squibb Company is led by Christopher Boerner and Kia Corporation is led by Ho Sung Song. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Kia Corporation?
Bristol-Myers Squibb Company was founded in 1887 — 57 years before Kia Corporation, which was founded in 1944. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Kia Corporation.
How many employees does Bristol-Myers Squibb Company have compared to Kia Corporation?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Kia Corporation employs approximately 53,200. Kia Corporation has the larger workforce at 53,200 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Kia Corporation headquartered?
Bristol-Myers Squibb Company is headquartered in United States and Kia Corporation is headquartered in South Korea. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Bristol-Myers Squibb Company and Kia Corporation?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Kia Corporation was founded by Kim Chul-ho.
Which company has a longer operating history — Bristol-Myers Squibb Company or Kia Corporation?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Kia Corporation has been in operation for around 82 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Kia overview